Currency in -
Last close As at 02/06/2023
-33.10
▲ 3.95 (13.55%)
Market capitalisation
266m
Research: TMT
IQE has recently announced the successful qualification, commencement of initial production and receipt of additional orders of wireless products destined for Asian supply chains, as well as the commencement of initial vertical cavity surface emitting laser (VCSEL) production for a second major customer at its new foundry in Newport. The share price has risen by 29% following the announcements, which demonstrate that IQE’s dominant position in the outsourced compound semiconductor epitaxy market gives resilience to reduced demand from individual customers.
IQE |
Demonstrating resilience to supply chain shifts |
Production and qualification updates |
Tech hardware & equipment |
29 July 2019 |
Share price performance Business description
Analysts
IQE is a research client of Edison Investment Research Limited |
IQE has recently announced the successful qualification, commencement of initial production and receipt of additional orders of wireless products destined for Asian supply chains, as well as the commencement of initial vertical cavity surface emitting laser (VCSEL) production for a second major customer at its new foundry in Newport. The share price has risen by 29% following the announcements, which demonstrate that IQE’s dominant position in the outsourced compound semiconductor epitaxy market gives resilience to reduced demand from individual customers.
Year end |
Revenue |
PBT* |
EPS* |
DPS |
P/E |
Yield |
12/17 |
154.5 |
24.5 |
3.38 |
0.0 |
20.0 |
N/A |
12/18 |
156.3 |
14.0 |
1.38 |
0.0 |
48.9 |
N/A |
12/19e |
147.2 |
5.4 |
0.52 |
0.0 |
129.8 |
N/A |
12/20e |
179.0 |
24.5 |
2.41 |
0.0 |
28.0 |
N/A |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
In June IQE cut its FY19 guidance, resulting in a 25% drop in the share price. Its customers manufacturing wireless semiconductor chips for the mobile phone industry were cutting back inventory levels in response to the uncertainty regarding future demand caused by lengthening mobile phone replacement cycles and the potential impact of Huawei’s addition to the US Bureau of Industry and Security’s Entity List. Additionally, a major photonics (not VCSEL) customer experienced an internal issue. We noted at the time that IQE’s dominant position made it is relatively agnostic to any mid- to long-term shifts in market share at either component or OEM level. The recent wireless qualifications validate this view, confirming that IQE is successfully embedded in new, Asia-centric supply chains.
On the photonics front, IQE has commenced VCSEL production at Newport for a second major customer, this one serving the Android supply chain, and is at the advanced qualification stage on several other VCSEL projects. In addition, the chip customer behind the 2017 VCSEL production ramp-up has extended its current contract until the end of 2021. These developments support our view that IQE will be able to offset loss of production for the major (non-VCSEL) photonics customer fairly rapidly.
|
|
Research: Healthcare
Shield Therapeutics’ primary asset, Feraccru, has been approved by the FDA for the treatment of iron deficiency in patients with any underlying cause – the broadest possible label. It will be marketed in the US as Accrufer. This is upside to our previous assumptions and increases our peak sales potential to c$420m (vs c $250m previously). Successfully commercialising Feraccru/Accrufer through partners is now key to Shield realising its value. We expect Shield to out-license the US rights during the next 18 months. An upfront licensing payment would extend Shield’s cash reach beyond our current forecast of H220. We now value Shield at £273m.
Get access to the very latest content matched to your personal investment style.